2026 Q1 -tulosraportti
25 päivää sitten7,00 DKK/osake
Viimeisin osinko
0,93 %Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
7 825
Myynti
Määrä
7 879
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 48 | - | - | ||
| 9 | - | - | ||
| 13 | - | - | ||
| 18 | - | - | ||
| 44 | - | - |
Ylin
751VWAP
Alin
741VaihtoMäärä
16,3 21 897
VWAP
Ylin
751Alin
741VaihtoMäärä
16,3 21 897
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2026 Q1 -tulosraportti | 11.11. | |
| 2026 Q1 -tulosraportti | 7.11. | |
| 2025 Q4 -tulosraportti | 12.9. | |
| 2025 Q4 -tulosraportti | 11.9. | |
| 2025 Q3 -tulosraportti | 7.5. |
Datan lähde: Quartr, FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·23.11.Sitting here tonight looking through companies to see if there's anything interesting. And then I stumbled upon Chemometec. 54.57% growth this year, that's impressive. So I wanted to investigate why and what would justify that growth. I mean... they have a revenue of 495 million 2024/25. Net profit of 186 million. OFC of 207 million. But they have a market capitalization of a whopping 13.2 billion?? They turn over 3.75% of their value? Guided revenue of 545-565 million and EBITDA 295-315 million. So what can justify this share price (751.5) with p/e 70.95, EPS 10.71 and B/P of 19.64. But then I see an EBIT margin of 47.7% and ROIC OF A WHOPPING 71%! So the stock is priced in for earnings to suddenly accelerate. Everything from 4%-59% sales growth in various countries (p. 25-28 in the 2024/25 report) where only two countries had single-digit growth, the rest increased nicely. So at first glance, they can boost sales. Q1 2025/26 just confirms guidance and an EBITDA margin of 55%. It might well be one you can buy and keep in the drawer for about 5 years and then pull it out again. But it will take time to get to know their products and find out if they are actually good, reasonable, or sought after.
·2.12. · MuokattuRegarding their products, they are highly sought after within gene and cell therapy. A rapidly growing market, especially in the USA where chemo is the market leader. Something unique about the company's business model is their ability to create continuous cash flow from existing customers through the "printer model". Just like with printers that customers constantly have to feed with ink cartridges, chemo's cell counter tool also needs to be fed with self-produced cassette systems and dye reagents. Super efficient and good for recurring revenue. However, the company's large customers are pressured by the fact that gene and cell therapy is costly, which has led to lower investments in the area in recent years. This challenge has clearly affected chemo, but has recently turned it into an opportunity: They are now focusing much more on solving this problem for customers through now fully automatic products and software, which is obviously more cost-effective. This transition is promising with great potential, but also crucial for the company's future growth and justification of the current valuation.
·19.11.The world's most boring stock, but thanks for a good year so far.
·25.11.Hmm, it's up YTD by 54%, and the last 10 years by 3100%. That's anything but boring.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
25 päivää sitten7,00 DKK/osake
Viimeisin osinko
0,93 %Tuotto/v
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23.11.Sitting here tonight looking through companies to see if there's anything interesting. And then I stumbled upon Chemometec. 54.57% growth this year, that's impressive. So I wanted to investigate why and what would justify that growth. I mean... they have a revenue of 495 million 2024/25. Net profit of 186 million. OFC of 207 million. But they have a market capitalization of a whopping 13.2 billion?? They turn over 3.75% of their value? Guided revenue of 545-565 million and EBITDA 295-315 million. So what can justify this share price (751.5) with p/e 70.95, EPS 10.71 and B/P of 19.64. But then I see an EBIT margin of 47.7% and ROIC OF A WHOPPING 71%! So the stock is priced in for earnings to suddenly accelerate. Everything from 4%-59% sales growth in various countries (p. 25-28 in the 2024/25 report) where only two countries had single-digit growth, the rest increased nicely. So at first glance, they can boost sales. Q1 2025/26 just confirms guidance and an EBITDA margin of 55%. It might well be one you can buy and keep in the drawer for about 5 years and then pull it out again. But it will take time to get to know their products and find out if they are actually good, reasonable, or sought after.·2.12. · MuokattuRegarding their products, they are highly sought after within gene and cell therapy. A rapidly growing market, especially in the USA where chemo is the market leader. Something unique about the company's business model is their ability to create continuous cash flow from existing customers through the "printer model". Just like with printers that customers constantly have to feed with ink cartridges, chemo's cell counter tool also needs to be fed with self-produced cassette systems and dye reagents. Super efficient and good for recurring revenue. However, the company's large customers are pressured by the fact that gene and cell therapy is costly, which has led to lower investments in the area in recent years. This challenge has clearly affected chemo, but has recently turned it into an opportunity: They are now focusing much more on solving this problem for customers through now fully automatic products and software, which is obviously more cost-effective. This transition is promising with great potential, but also crucial for the company's future growth and justification of the current valuation.
- ·19.11.The world's most boring stock, but thanks for a good year so far.·25.11.Hmm, it's up YTD by 54%, and the last 10 years by 3100%. That's anything but boring.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
7 825
Myynti
Määrä
7 879
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 48 | - | - | ||
| 9 | - | - | ||
| 13 | - | - | ||
| 18 | - | - | ||
| 44 | - | - |
Ylin
751VWAP
Alin
741VaihtoMäärä
16,3 21 897
VWAP
Ylin
751Alin
741VaihtoMäärä
16,3 21 897
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2026 Q1 -tulosraportti | 11.11. | |
| 2026 Q1 -tulosraportti | 7.11. | |
| 2025 Q4 -tulosraportti | 12.9. | |
| 2025 Q4 -tulosraportti | 11.9. | |
| 2025 Q3 -tulosraportti | 7.5. |
Datan lähde: Quartr, FactSet
2026 Q1 -tulosraportti
25 päivää sittenUutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2026 Q2 -tulosraportti | 4.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2026 Q1 -tulosraportti | 11.11. | |
| 2026 Q1 -tulosraportti | 7.11. | |
| 2025 Q4 -tulosraportti | 12.9. | |
| 2025 Q4 -tulosraportti | 11.9. | |
| 2025 Q3 -tulosraportti | 7.5. |
Datan lähde: Quartr, FactSet
7,00 DKK/osake
Viimeisin osinko
0,93 %Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·23.11.Sitting here tonight looking through companies to see if there's anything interesting. And then I stumbled upon Chemometec. 54.57% growth this year, that's impressive. So I wanted to investigate why and what would justify that growth. I mean... they have a revenue of 495 million 2024/25. Net profit of 186 million. OFC of 207 million. But they have a market capitalization of a whopping 13.2 billion?? They turn over 3.75% of their value? Guided revenue of 545-565 million and EBITDA 295-315 million. So what can justify this share price (751.5) with p/e 70.95, EPS 10.71 and B/P of 19.64. But then I see an EBIT margin of 47.7% and ROIC OF A WHOPPING 71%! So the stock is priced in for earnings to suddenly accelerate. Everything from 4%-59% sales growth in various countries (p. 25-28 in the 2024/25 report) where only two countries had single-digit growth, the rest increased nicely. So at first glance, they can boost sales. Q1 2025/26 just confirms guidance and an EBITDA margin of 55%. It might well be one you can buy and keep in the drawer for about 5 years and then pull it out again. But it will take time to get to know their products and find out if they are actually good, reasonable, or sought after.·2.12. · MuokattuRegarding their products, they are highly sought after within gene and cell therapy. A rapidly growing market, especially in the USA where chemo is the market leader. Something unique about the company's business model is their ability to create continuous cash flow from existing customers through the "printer model". Just like with printers that customers constantly have to feed with ink cartridges, chemo's cell counter tool also needs to be fed with self-produced cassette systems and dye reagents. Super efficient and good for recurring revenue. However, the company's large customers are pressured by the fact that gene and cell therapy is costly, which has led to lower investments in the area in recent years. This challenge has clearly affected chemo, but has recently turned it into an opportunity: They are now focusing much more on solving this problem for customers through now fully automatic products and software, which is obviously more cost-effective. This transition is promising with great potential, but also crucial for the company's future growth and justification of the current valuation.
- ·19.11.The world's most boring stock, but thanks for a good year so far.·25.11.Hmm, it's up YTD by 54%, and the last 10 years by 3100%. That's anything but boring.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
7 825
Myynti
Määrä
7 879
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 48 | - | - | ||
| 9 | - | - | ||
| 13 | - | - | ||
| 18 | - | - | ||
| 44 | - | - |
Ylin
751VWAP
Alin
741VaihtoMäärä
16,3 21 897
VWAP
Ylin
751Alin
741VaihtoMäärä
16,3 21 897
Välittäjätilasto
Dataa ei löytynyt